Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URSONASH: Ursodesoxycholic Acid in NASH
NCT00470171Phase 2Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Oct 2005
- Primary completion
- Nov 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Ursodesoxycholic acid with Placebo (2 arms). Primary endpoint: Alanine Aminotransferase at 12 months. Started Oct 2005; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00470171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470171.